InflaRx N.V. IFRX
1.21 USD -0.10 (-7.63%)
At closeNov 10, 2026, 4:00 PM EST
1.21 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
1.21 Day range 1.40
0.798 52-week range 2.95
- YTD
- +19.80%
- 1 year
- -23.42%
News
benzinga.com InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses…
globenewswire.com InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced…
seekingalpha.com InflaRx N.V. (IFRX) Analyst/Investor Day Transcript InflaRx N.V. ( IFRX ) Analyst/Investor Day November 3, 2026 8:00 AM EST Company Participants Jan Medina - Head of Investor Relations & VP Niels Riedemann - Co-Founder, CEO & Executive Director Thomas…
marketbeat.com InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials InflaRx NASDAQ: IFRX outlined plans to advance its oral C5a receptor antagonist izicopan in ANCA-associated vasculitis (AAV), with an initial focus on patients with kidney involvement and a parallel…
benzinga.com InflaRx Q3 EPS $(0.02) Beats $(0.07) Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 90.48 percent increase over losses of $(0.21) per…
globenewswire.com InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
benzinga.com This GE Vernova Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday Analysts initiate: Sell GEV ($470); Buy IFRX ($8), LYNX ($21); Overweight FRSH ($18); Outperform NPWR ($2.75).
benzinga.com Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8 Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $8.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…
benzinga.com Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6 Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
benzinga.com InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per…- benzinga.com InflaRx Mulls Feasibility For AAV In Europe InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening…
- benzinga.com Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9 Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy and raises the price target from $7 to $9.
- benzinga.com HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8 HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.
- benzinga.com Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4 Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions.The Company intends to…- benzinga.com InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com InflaRx Regains Nasdaq Compliance InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written…
- benzinga.com 10 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com InflaRx Announces New In Vitro Findings Demonstrating That Izicopan Does Not Exhibit Time-Dependent Inhibition Of CYP3A4, Indicator For Risk For Ddis And Liver Toxicity InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan…- benzinga.com InflaRx Highlights Data From Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum At 2026 AAD Annual Meeting InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab…
- benzinga.com Guggenheim Maintains Buy on InflaRx, Lowers Price Target to $14 Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $22 to $14.
- benzinga.com InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 88.89 percent decrease over losses of $(0.09) per…
benzinga.com Earnings Scheduled For March 19, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com InflaRx Presents Oral Presentation At 2026 American Academy Of Dermatology Annual Meeting InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral presentation during the Late-Breaking…
- benzinga.com InflaRx Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the…
benzinga.com InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway InflaRx outlines restructuring plans, workforce cuts, and reduced Gohibic spending to extend cash runway and focus development efforts on izicopan through mid-2027.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.- benzinga.com HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $6 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $6 price target.
benzinga.com InflaRx Outlined Multiple Data Analyses Of The Phase 3 Study For Vilobelimab In Pyoderma Gangrenosum, Which Was Terminated Earlier In 2025 After An Independent Data Monitoring Committee Recommended To Stop The Trial Early Due To Futility While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed),…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Leerink Partners Downgrades InflaRx to Market Perform, Lowers Price Target to $2 Leerink Partners analyst Joseph Schwartz downgrades InflaRx (NASDAQ:IFRX) from Outperform to Market Perform and lowers the price target from $5 to $2.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Is InflaRx NV Gaining or Losing Market Support?
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Guggenheim Maintains Buy on InflaRx, Raises Price Target to $22 Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $10 to $22.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - benzinga.com InflaRx To Present Data From Phase 2a Clinical Study Of Oral C5ar Inhibitor INF904 In Participants With Hidradenitis Suppurativa And Chronic Spontaneous Urticaria On Nov. 10 InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it expects to report topline data from the…
benzinga.com Biogen's Immunology Pipeline Has Long-Term Potential: Analyst Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.- benzinga.com InflaRx Regains Nasdaq Compliance InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written…
benzinga.com Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
benzinga.com HC Wainwright & Co. Assumes InflaRx at Buy, Announces Price Target of $6 HC Wainwright & Co. analyst Matthew Keller assumes InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $6.